A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company’s lawyers sent an email with the wrong opposition deadline.
Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.
The CSIRO is appealing a decision by the Commissioner of Patents that allowed chemical giant BASF to amend its application for a genetically modified organisms patent.
Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.
Ramsay Health Care has defeated a challenge to its Nuramel trade mark for a brand of infant formula, with IP Australia saying while the mark was an exact anagram of Biofarma’s Munarel, it wasn’t deceptively similar.
GlaxoSmithKline has won approval for a patent for a vaccine to prevent a common respiratory virus affecting infants, beating out a challenge from a rival that has developed a competing vaccine.
Animal drug giant Merial is pushing on with its opposition to rival Intervet’s bid to a patent a non-drug resistant injectable formula for treating animal parasites, filing an appeal in the Federal Court after it came up short in its challenge before IP Australia.